BridgeBio Oncology Therapeutics (BBOT) Cash from Financing Activities (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Cash from Financing Activities for 3 years, with the latest figure at $295000.0 in Q1 2026.

• Quarterly Cash from Financing Activities rose 173.02% year-over-year to $295000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$643000.0 (down 103.31% YoY) and the FY2025 annual result came in at $383.4 million, up 85.86% from the prior year.
• Cash from Financing Activities grew to $295000.0 in Q1 2026 per BBOT's latest filing, from -$586000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $186.5 million in Q1 2024 and troughed at -$586000.0 in Q4 2025.
• A 3-year average of $34.3 million and a median of $173500.0 in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities plunged 1226.92% in 2025, then jumped 173.02% in 2026.
• Over 3 years, Cash from Financing Activities stood at $52000.0 in 2024, then slumped by 1226.92% to -$586000.0 in 2025, then soared by 150.34% to $295000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $295000.0, -$586000.0, and -$404000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.